Browse the evidence

Tirzepatide resulted in mean waist circumference reductions ranging from 4.3 to 9.8 cm across subgroups.

Tirzepatide is effective in reducing waist circumference in East Asian individuals with type 2 diabetes.

Recently developed therapeutics may enable effective management of body weight in patients with obesity.

Healthcare providers may consider new therapeutics for obesity management.

Semaglutide showed the most significant weight reduction among patients with IBD.

Semaglutide may be effective for weight management in IBD patients.

The use of GLP-1 receptor agonists (GLP-1RAs) post-bariatric treatment results in a weight reduction of 7.83 kg compared to pre-treatment.

GLP-1RAs can be an effective strategy for weight management in patients after bariatric surgery.

In randomized controlled trials, GLP-1RAs induce a weight reduction of 4.36 kg compared to placebo.

GLP-1RAs can be beneficial for weight loss in a controlled setting post-bariatric surgery.

GLP-1 receptor agonists provide an effective alternative to metabolic surgery and dietary interventions for obesity treatment.

GLP-1 receptor agonists may be recommended as a non-surgical option for managing obesity.

Training increased muscle strength by approximately 20%-126%, muscle thickness by approximately 8%-11%, and average fiber cross-sectional area by approximately 15%-20%.

Resistance training significantly enhances muscle strength and size in both sexes.

MyoPS is positively associated with muscle thickness and fiber cross-sectional area only in the trained state for both sexes.

Monitoring MyoPS can be important for assessing muscle growth in trained individuals.

Retatrutide and orforglipron are effective in weight loss and improving metabolic parameters associated with obesity.

These drugs may be considered as therapeutic options for obesity management.

Weight reduction and management strategies may improve chronic kidney disease outcomes.

Weight management should be considered as part of CKD treatment plans.

Semaglutide led to a weight reduction of 9.21 kg in the study population.

Semaglutide may assist in significant weight loss for patients in this demographic.

Combined nutrition and exercise interventions significantly reduced body weight by 2.13 kg (95%CI, -3.07 to -1.19) in adults with cancer.

Practitioners can consider combined nutrition and exercise interventions as effective strategies for weight management in cancer patients.

Combined nutrition and exercise interventions significantly reduced fat mass by 2.06 kg (95%CI, -3.02 to -1.09) in adults with cancer.

Practitioners can utilize combined nutrition and exercise interventions to effectively reduce fat mass in cancer patients.

Recent guidelines emphasize the importance of diagnosing and treating obesity to prevent CVD.

Clinicians should follow guidelines to effectively manage obesity in patients to reduce CVD risk.

Incretin hormone agonists offer substantial weight reduction and cardiometabolic benefits.

Practitioners can consider incretin hormone agonists as effective options for obesity management.

The working group recommends dietary consultations, increased physical activity, resistance training, and potential use of oral nutritional supplements and medications for managing sarcopenic obesity.

Practitioners should consider these recommendations for effective management of sarcopenic obesity.

Resistance-based exercise programs resulted in a significant change of -1.6 kg in whole-body fat mass (95% CI = -1.9 to -1.3 kg, P < 0.001).

Resistance training can effectively reduce body fat in overweight and obese individuals.

Resistance-based exercise programs resulted in a significant change of +0.8 kg in lean mass (95% CI = 0.6 to 0.9 kg, P < 0.001).

Resistance training can effectively increase muscle mass in overweight and obese individuals.

Factors that mediate the long-term effectiveness of resistance exercise stimuli include optimizing dose and recovery.

Focus on optimizing training dose and recovery to enhance long-term strength outcomes.

Semaglutide has been shown to result in a loss of almost 12% of body weight over a 68-week period.

Semaglutide can be considered an effective option for significant weight loss in eligible patients.

Supplementation with long-chain omega-3 fatty acids and increasing the consumption of alpha-linolenic and linoleic acids in place of saturated fats reduced the risk of coronary events.

Encouraging omega-3 supplementation and specific fatty acid intake may help reduce coronary event risk.

Weight loss reduced CRP levels by 33.5% and IL-6 levels by 41.9%.

Weight loss can significantly lower inflammation markers associated with obesity.

Weight loss effectively reduces proinflammatory markers and hormones associated with increased risk of endometrioid EC.

Reducing weight can lower the risk factors for endometrial cancer in obese individuals.

Emerging antidiabetic medications show impressive antihyperglycemic effects and remarkable weight loss.

Practitioners should consider these new medications for managing T2D due to their dual benefits.